Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta

Journal of Bone and Mineral Metabolism

Volumn 29, Issue 5, 2011, Pages 598-605

  Kitaoka, Taichi ^a   Namba, Noriyuki ^a   Miura, Kohji ^a   Kubota, Takuo ^a   Ohata, Yasuhisa ^a   Fujiwara, Makoto ^a   Hirai, Haruhiko ^a   Yamamoto, Takehisa ^b   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Minoh City Hospital   (Japan)

Author keywords

Bisphosphonate; FGF23; Hypocalcemia; Hypophosphatemia; Osteogenesis imperfecta

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHORUS;

ADOLESCENT; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG EFFECT; FEMALE; FEVER; GRAND MAL SEIZURE; HAND PARESTHESIA; HUMAN; INFANT; JAW OSTEONECROSIS; KIDNEY TUBULE ABSORPTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA;

EID: 83155176197     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-011-0262-z     Document Type: Article

References (30)

1. ADHR Consortium (2000) Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
2. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumorinduced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505 (Pubitemid 32488266)
3. Fukumoto S, Yamashita T (2007) FGF23 is a hormone-regulating phosphate metabolism: unique biological characteristics of FGF23. Bone (NY) 40:1190-1195 (Pubitemid 46550981)
4. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T (2009) Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone (NY) 45:814-816
5. Itoh N, Ornitz DM (2004) Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563-569 (Pubitemid 39314564)
6. Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637-1647 (Pubitemid 46870300)
7. Kuro-o M (2006) Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 15:437-441
8. Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone (NY) 35:1192-1199 (Pubitemid 39487366)
9. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N (2007) Mineralized tissue cells are a principal source of FGF23. Bone (NY) 40:1565-1573 (Pubitemid 46756409)
10. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/ osteomalacia. J Clin Endocrinol Metab 87:4957-4960 (Pubitemid 35316332)
11. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone (NY) 42:1235-1239
12. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E (2006) Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70:2141-2147 (Pubitemid 44871378)
13. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA (2005) Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1, 25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358-5364 (Pubitemid 41653049)
14. Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 25:1367-1374
15. Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A, Flor AW, Mulvihill JJ, Wilson PL, Sundaram UT, Lee B, Marini JC (2006) Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med 355:2757-2764 (Pubitemid 46021513)
16. Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC (2007) Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 39:359-365 (Pubitemid 46328489)
17. Barnes AM, Carter EM, Cabral WA, Weis M, Chang W, Makareeva E, Leikin S, Rotimi CN, Eyre DR, Raggio CL, Marini JC (2010) Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med 362:521-528
18. Sillence DO, Senn AS, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116 (Pubitemid 9164903)
19. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM (2010) Classification of osteogenesis imperfecta revisited. Eur J Med Genet 53:1-5
20. Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299 (Pubitemid 35285755)
21. Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD (2004) Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 24:195-197 (Pubitemid 38209439)
22. DiMeglio LA, Ford L, McClintock C, Peacock M (2004) Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone (NY) 35:1038-1045 (Pubitemid 39487349)
23. Castillo H, Samson-Fang L (2009) American Academy for Cerebral Palsy, Developmental Medicine Treatment Outcomes Committee Review Panel Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 51:17-29
24. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986-992 (Pubitemid 36337744)
25. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850 (Pubitemid 32269287)
26. Silver J, Navey-Many T (2010) FGF23 and the parathyroid glands. Pediatr Nephrol 25:2241-2245
27. Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers T (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone (NY) 42:200-211 (Pubitemid 350302017)
28. Plotkin LI, Manolagas SC, Bellido T (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone (NY) 39:443-452 (Pubitemid 44164640)
29. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone (NY) 42:848-860
30. Yamamoto T, Imanishi Y, Kinoshita E, Nakagomi Y, Shimizu N, Miyauchi A, Satomura K, Koshiyama H, Inaba M, Nishizawa Y, Juppner H, Ozono K (2005) The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab 23:231-237 (Pubitemid 40603206)